SOLICITATION NOTICE
B -- Completing the Measurement of Estrogens, Androgens, and Progestagens in an Expanded Case-Control Study of Breast Cancer Nested in the PLCO Cohort
- Notice Date
- 8/8/2018
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP82635-36
- Archive Date
- 9/1/2018
- Point of Contact
- David H. Romley, Phone: 2402767822
- E-Mail Address
-
david.romley@nih.gov
(david.romley@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- General Information Short Title: Completing the Measurement of Estrogens, Androgens, and Progestagens in an Expanded Case-Control Study of Breast Cancer Nested in the PLCO Cohort Document Type: Presolicitation Notice Solicitation Number: N02CP82635-36 Posted Date: 8/8/2018 Response Date: 8/17/2018 Classification Code: B - Special Studies and Analyses - Not R&D NAICS Code: 541990 - All Other Professional, Scientific and Technical Services Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E232 Bethesda, MD 20892, UNITED STATES Description The Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP) plans to apply the liquid chromatography-tandem mass spectrometry (LC-MS/MS) multiple steroid hormone assay developed by the Centers for Disease Control and Prevention (CDC) in a case-control study of breast cancer nested in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. All women will be postmenopausal and not currently using exogenous hormones at time of blood draw. The EBP plans to include the breast cancer cases and matched controls in the PLCO cohort for whom the EBP has already measured estrogen metabolism profiles, IGF-I and IGFBP-3, vitamin D metabolites, and prolactin. In addition, the EBP plans to include additional breast cancer cases diagnosed since completion of the initial study who have prediagnostic serum samples, along with matched controls. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial items and will be made pursuant to the authority in FAR 13.106-1(b)(1) using simplified acquisition procedures for commercial items. The North American Industry Classification System code is 541990 and the business size standard is $15,000,000. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. A panel of steroid hormones (estrone sulfate, estrone, estradiol, DHEAS, androstenedione, testosterone, progesterone, and 17-hydroxyprogesterone) will be measured in 308 serum samples using an accurate, precise, sensitive isotope dilution LC-MS/MS method. Contractor Requirements The Contractor shall: 1) Provide updated performance characteristics of the LC-MS/MS assay, including accuracy, reproducibility, and sensitivity. 2) Measure a panel of steroid hormones (estrone sulfate, estrone, estradiol, DHEAS, androstenedione, testosterone, progesterone, and 17-hydroxyprogesterone) in 308 serum samples using an accurate, precise, sensitive isotope dilution LC-MS/MS method. 3) Provide the results of the assays to the NCI Technical Point of Contact (TPC). Results shall be provided within one month of completion of the assays. Governments Responsibilities NCI will: 1) Ensure that the NCI ships the 308 serum samples to be assayed directly to the Contractor within three months after the award. Aliquots of 600 microL will be frozen at -70°C, packed with dry ice, and shipped, via overnight courier, to the Contractor. 2) Provide the Contractor with an electronic manifest containing anonymized identification numbers for each sample at the time the samples are shipped. 3) Review the assay results within one month of receiving the data. At that time, the TPC will determine if the objective of the procurement is met, based on the data provided by the Contractor. The assay must be validated for estradiol and testosterone through the CDC Hormone Standardization Program. No commercial, academic, or government laboratory in the world has an assay that measures the seven major female steroid hormones (estrone sulfate, estrone, estradiol, DHEAS, androstenedione, testosterone, progesterone) with the accuracy, precision, and sensitivity demonstrated by the CDC assay. Specifically, the assay is sensitive enough to measure serum concentrations for the seven steroid hormones listed above in nearly all postmenopausal women. There is no assay even remotely comparable at any other laboratory in the world. Indeed CDC was encouraged to develop this assay in its own laboratories because no equivalent assay existed commercially and this type of assay was needed for national US health surveys and etiologic research. Therefore, CDC is the only known source that can meet NCI's needs at this time. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 12:00 PM EST, on August 17, 2018. All responses and questions must be in writing and faxed 240-276-5401 or emailed to David Romley, Contract Specialist OR via electronic mail at david.romley@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP82635-36 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP82635-36 /listing.html)
- Record
- SN05028039-W 20180810/180808231724-3eb8a2783d3e3306a571496d3e4f7edc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |